<\/p>\n
A clandestine increase of the deadly fungus Candida auris is sweeping UK hospitals, with infections rising and resistance growing, raising concerns over public health preparedness and transparency.<\/p>\n<\/div>\n
A clandestine surge of the deadly fungus Candida auris is currently sweeping through UK hospitals, according to a leaked dossier from the UK Health Security Agency (UKHSA) seen by The Mail on Sunday. The highly infectious fungus, formally designated as Candidozyma auris, is responsible for significant outbreaks and poses a grave threat to public health, with mortality rates internationally reported to approach 60% within 90 days of infection. Its silent spread across 72 hospitals in the past two years signals a troubling escalation of risk that health authorities appear underprepared to manage effectively.<\/p>\n
Candida auris is an insidious pathogen, often lying dormant on surfaces and human skin, undetectable until it invades the bloodstream through cuts or abrasions, where it becomes life-threatening, particularly for patients with weakened immune systems. The fungus exhibits growing resistance to antifungal treatments, complicating efforts to eradicate it. UK hospitals have documented contamination on radiators, windowsills, and medical equipment, highlighting the challenge of containment. In April, UKHSA escalated its classification of C. auris to a \u2018schedule 2\u2019 illness, a status previously reserved for the UK\u2019s most serious diseases, underscoring the urgency of the threat.<\/p>\n
Despite these alarming developments, NHS reporting is incomplete, and official data on mortality rates remain undisclosed, prompting concerns among politicians and experts. Tory health spokesman Stuart Andrew criticised UKHSA\u2019s perceived lack of transparency, warning that withholding information undermines public confidence and safety. UKHSA acknowledges ongoing outbreaks across the country, with a notable cluster at Guy\u2019s and St Thomas\u2019s Hospital in London accounting for 222 cases, although the proportion of invasive bloodstream infections remains unclear. UKHSA representative Rohini Manuel indicated that investigations are underway to identify causes and assist hospital trusts in controlling the fungus\u2019s spread.<\/p>\n
Detailed reports from government sources reveal that since 2015, the UK has experienced at least five major outbreaks involving over 50 cases each, primarily in surgical critical care and specialised wards such as neurosurgery and cardiothoracic units. These outbreaks have been profoundly disruptive and costly, with one instance incurring over \u00a31 million in control measures over seven months. The infection\u2019s persistence and emergence appear to be independent of foreign healthcare links, suggesting that Candida auris is becoming endemic within certain UK hospital environments. Factors influencing the outbreaks include patient vulnerability, healthcare infrastructure, and local epidemiology, emphasising the need for robust infection prevention and control protocols.<\/p>\n
Data through April 2025 further indicate that cases are rising, with 134 new Candida auris instances reported in England from November 2024 to April 2025, a 23% increase from the previous period. Most cases were non-invasive colonisations, but invasive infections continue to pose significant risks. Notably, twelve healthcare providers reported C. auris cases for the first time during this period, highlighting its expanding geographical footprint. London remains the epicentre, with the highest incidence rate nationally.<\/p>\n
Candida auris is not confined to the UK; it is a growing problem across Europe. Between 2013 and 2023, over 4,000 cases were reported across EU countries, with a surge to 1,346 in 2023 alone. Countries including Spain, Greece, Italy, Romania, and Germany have reported substantial outbreaks, and several others have recently seen infections. The European Centre for Disease Prevention and Control warns that in some regions of Europe, the fungus is approaching endemic levels within hospital settings, amplifying the urgency for improved surveillance and control.<\/p>\n
The fungus\u2019s resilience lies in its ability to adhere strongly to surfaces through proteins called adhesins, making it exceptionally difficult to eradicate from hospital environments once established. Treatment challenges are compounded by resistance of some strains to nearly all antifungal drugs, contributing to a high fatality rate, particularly among severely ill or immunocompromised patients.<\/p>\n
Responding to the rising threat, the UKHSA has reported a small but notable increase in serious yeast bloodstream infections in 2024 compared to 2023, including C. auris cases. Total recorded cases since 2013 have reached 637, with 178 reported in 2024 alone. Post-pandemic travel and altered healthcare dynamics may have contributed to this resurgence. To enhance public health responses, C. auris has been designated a notifiable disease in England, mandating all laboratories to report cases. Additionally, the UKHSA has published updated guidance for healthcare professionals to manage outbreaks more effectively.<\/p>\n
While the fungus remains rare compared to other infectious agents, its deadly potential, resistance patterns, and difficulty in control represent a significant challenge for the NHS and wider public health. The current situation highlights the critical need for transparency, enhanced infection control measures, and ongoing vigilance to curb what may become an entrenched pathogen in healthcare settings.<\/p>\n